Alberto Bardelli, Bs

List of Publications by Year
in descending order

261 papers	57,072 citations	95 h-index	232 g-index
		2675	1091
272 all docs	272 docs citations	272 times ranked	53008 citing authors

#	Article	IF	Citations
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
2	High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science, 2004, 304, 554-554.	12.6	3,048
3	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	1.2	2,545
4	International network of cancer genome projects. Nature, 2010, 464, 993-998.	27.8	2,114
5	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	10.7	1,915
6	Liquid Biopsies: Genotyping Circulating Tumor DNA. Journal of Clinical Oncology, 2014, 32, 579-586.	1.6	1,811
7	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103.	27.8	1,769
8	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
9	Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 5705-5712.	1.6	1,540
10	Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 2013, 10, 472-484.	27.6	1,482
11	Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 2017, 14, 531-548.	27.6	1,375
12	RAF/RAS oncogenes and mismatch-repair status. Nature, 2002, 418, 934-934.	27.8	1,110
13	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 1994, 77, 261-271.	28.9	980
14	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncology, The, 2005, 6, 279-286.	10.7	924
15	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	9.4	818
16	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
17	Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Antiâ€“Epidermal Growth Factor Receptor Antibody Therapies. Cancer Research, 2007, 67, 2643-2648.	0.9	801
18	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	10.7	778

#	Article	IF	Citations
19	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 2016, 22, 262-269.	30.7	768
20	PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. Cancer Research, 2009, 69, 1851-1857.	0.9	711
21	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	27.8	702
22	Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 1254-1261.	1.6	668
23	Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA - Journal of the American Medical Association, 2010, 304, 1812.	7.4	663
24	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	30.7	604
25	A Phosphatase Associated with Metastasis of Colorectal Cancer. Science, 2001, 294, 1343-1346.	12.6	601
26	Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
27	Mutations in a signalling pathway. Nature, 2005, 436, 792-792.	27.8	510
28	Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers. Science, 2004, 304, 1164-1166.	12.6	498
29	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptorâ€“Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	6.3	486
30	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 1998, 391, 285-288.	27.8	485
31	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
32	Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 8816-8820.	0.9	472
33	Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers. Science, 2003, 300, 949-949.	12.6	436
34	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415
35	Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell, 2017, 31, 172-179.	16.8	395
36	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusionâ€“Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	9.4	384

#	Article	IF	Citations
37	Earlyâ€onset colorectal cancer in young individuals. Molecular Oncology, 2019, 13, 109-131.	4.6	365
38	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	30.7	359
39	IDH1mutations at residue p.R132 (IDH1^{R132}) occur frequently in high-grade gliomas but not in other solid tumors. Human Mutation, 2009, 30, 7-11.	2.5	348
40	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
41	PIK3CAmutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptorâ€"positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10208-10213.	7.1	324
42	Antibodyâ€"Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€"small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999.	7.0	315
43	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation, 2010, 120, 2858-2866.	8.2	309
44	Adaptive mutability of colorectal cancers in response to targeted therapies. Science, 2019, 366, 1473-1480.	12.6	290
45	Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93.	6.4	266
46	The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathologica, 2010, 119, 487-494.	7.7	262
47	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discovery, 2016, 6, 36-44.	9.4	258
48	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€"Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	9.4	254
49	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	12.8	251
50	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	9.4	245
51	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nature Medicine, 2018, 24, 961-967.	30.7	244
52	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. PLoS ONE, 2009, 4, e7287.	2.5	241
53	Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction. Journal of Biological Chemistry, 1995, 270, 603-611.	3.4	232
54	How liquid biopsies can change clinical practice in oncology. Annals of Oncology, 2019, 30, 1580-1590.	1.2	231

#	Article	IF	Citations
55	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Science Translational Medicine, 2014, 6, 224ra26.	12.4	228
56	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	7.0	227
57	The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nature Medicine, 2016, 22, 624-631.	30.7	214
58	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.	12.1	188
59	Alterations in Vascular Gene Expression in Invasive Breast Carcinoma. Cancer Research, 2004, 64, 7857-7866.	0.9	183
60	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	183
61	AKT1E17K in human solid tumours. Oncogene, 2008, 27, 5648-5650.	5.9	181
62	A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor.. Molecular and Cellular Biology, 1993, 13, 4600-4608.	2.3	180
63	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology, 2018, 29, 1108-1119.	1.2	177
64	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3089-3094.	7.1	175
65	The Full Oncogenic Activity of Ret/ptc2 Depends on Tyrosine 539, a Docking Site for Phospholipase Cî³. Molecular and Cellular Biology, 1996, 16, 2151-2163.	2.3	173
66	Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clinical Cancer Research, 2012, 18, 2515-2525.	7.0	172
67	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications, 2016, 7, 13665.	12.8	170
68	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Reports, 2015, 12, 1978-1985.	6.4	163
69	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy inMET-Amplified Esophagogastric Cancer. Cancer Discovery, 2015, 5, 1271-1281.	9.4	162
70	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncology, 2014, 16, 1263-1273.	1.2	159
71	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	9.4	158
72	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clinical Cancer Research, 2013, 19, 2381-2392.	7.0	157

#	Article	IF	Citations
73	PRL-3 expression in metastatic cancers. Clinical Cancer Research, 2003, 9, 5607-15.	7.0	155
74	KRAS gene amplification in colorectal cancer and impact on response to EGFRâ€targeted therapy. International Journal of Cancer, 2013, 133, 1259-1265.	5.1	154
75	Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma. Cancer Research, 2007, 67, 3545-3550.	0.9	153
76	Carcinogen-specific induction of genetic instability. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5770-5775.	7.1	151
77	Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 2011, 17, 4901-4914.	7.0	150
78	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2017, 14, 562-576.	27.6	150
79	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer, 2010, 10, 631.	2.6	149
80	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 2414-2422.	7.0	148
81	High-dose vitamin C enhances cancer immunotherapy. Science Translational Medicine, 2020, 12, .	12.4	143
82	Specific Uncoupling of GRB2 from the Met Receptor. Journal of Biological Chemistry, 1996, 271, 14119-14123.	3.4	141
83	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene, 1999, 18, 5221-5231.	5.9	139
84	PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth. Clinical Cancer Research, 2005, 11, 6835-6839.	7.0	134
85	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer, 2009, 101, 1261-1268.	6.4	130
86	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell, 2018, 34, 148-162.e7.	16.8	129
87	Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene, 1997, 15, 3103-3111.	5.9	122
88	Acquired resistance to EGFRâ€targeted therapies inÂcolorectal cancer. Molecular Oncology, 2014, 8, 1084-1094.	4.6	121
89	PIK3CAcancer mutations display gender and tissue specificity patterns. Human Mutation, 2008, 29, 284-288.	2.5	120
90	Precision oncology in metastatic colorectal cancer â€" from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	27.6	113

#	Article	IF	Citations
91	Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3046-3053.	7.0	112
92	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
93	Exploring the links between cancer and placenta development. Open Biology, 2018, 8, .	3.6	109
94	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology, 2015, 26, 1994-1999.	1.2	105
95	RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells. Cell Reports, 2014, 8, 1475-1483.	6.4	103
96	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research, 2020, 26, 1624-1632.	7.0	103
97	Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treatment Reviews, 2014, 40, 648-655.	7.7	101
98	TGFÎ± and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells. Clinical Cancer Research, 2014, 20, 6429-6438.	7.0	101
99	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Cancer Research, 2016, 76, 7181-7193.	0.9	99
100	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. JAMA Oncology, 2018, 4, e175245.	7.1	98
101	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications, 2015, 6, 8305.	12.8	97
102	Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14379-14383.	7.1	96
103	Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Annals of Oncology, 2019, 30, 211-218.	1.2	96
104	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20864-20869.	7.1	95
105	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	3.7	95
106	Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97.	27.6	94
107	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open, 2020, 5, e000911.	4.5	94
108	Different point mutations in the met oncogene elicit distinct biological properties. FASEB Journal, 2000, 14, 399-406.	0.5	93

#	Article	IF	Citations
109	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
110	A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13868-13872.	7.1	90
111	Exploiting <scp>DNA</scp> repair defects in colorectal cancer. Molecular Oncology, 2019, 13, 681-700.	4.6	90
112	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition inBRAF-Mutated Colorectal Cancer. Cancer Discovery, 2016, 6, 963-971.	9.4	85
113	Identifying tumor origin using a gene expression-based classification map. Cancer Research, 2003, 63, 4144-9.	0.9	84
114	Novel mutation in the ATP-binding site of theMET oncogene tyrosine kinase in a HPRCC family. , 1999, 82, 640-643.		82
115	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine, 2016, 8, 324ra14.	12.4	81
116	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 2016, 27, 1443-1448.	1.2	79
117	Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene, 1999, 18, 1139-1146.	5.9	77
118	Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biology, 2014, 15, 449.	8.8	77
119	The Clinical Impact of the Genomic Landscape of Mismatch Repairâ€“Deficient Cancers. Cancer Discovery, 2018, 8, 1518-1528.	9.4	77
120	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Annals of Oncology, 2018, 29, 119-126.	1.2	76
121	Expression and Functional Regulation of Myoglobin in Epithelial Cancers. American Journal of Pathology, 2009, 175, 201-206.	3.8	74
122	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Annals of Oncology, 2018, 29, 1394-1401.	1.2	72
123	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell, 2016, 165, 317-330.	28.9	70
124	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treatment Reviews, 2019, 73, 41-53.	7.7	69
125	SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16897-16902.	7.1	68
126	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	7.0	66

#	Article	IF	Citations
127	Mutational Profile of GNAQQ209 in Human Tumors. PLoS ONE, 2009, 4, e6833.	2.5	63
128	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 3260-3267.	7.0	62
129	MET mutations in cancers of unknown primary origin (CUPs). Human Mutation, 2011, 32, 44-50.	2.5	61
130	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	10.7	61
131	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE, 2016, 11, e0149099.	2.5	60
132	A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth. Journal of Biological Chemistry, 1999, 274, 29274-29281.	3.4	59
133	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. Oncogene, 1999, 18, 4275-4281.	5.9	58
134	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Annals of Oncology, 2020, 31, 1135-1147.	1.2	58
135	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Annals of Oncology, 2011, 22, 2424-2430.	1.2	57
136	Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene. Current Drug Targets, 2001, 2, 41-55.	2.1	56
137	The road to resistance: EGFR mutation and cetuximab. Nature Medicine, 2012, 18, 199-200.	30.7	56
138	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open, 2017, 2, e000253.	4.5	56
139	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 256-262.e2.	2.3	56
140	Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. Journal of Biotechnology, 1994, 37, 109-122.	3.8	54
141	Loss of AXIN1 drives acquired resistance to <scp>WNT</scp> pathway blockade in colorectal cancer cells carrying <scp>RSPO</scp> 3 fusions. EMBO Molecular Medicine, 2017, 9, 293-303.	6.9	54
142	The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. Journal of Experimental and Clinical Cancer Research, 2010, 29, 32.	8.6	53
143	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	7.0	53
144	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. Journal of Clinical Oncology, 2021, 39, 3506-3506.	1.6	53

#	Article	IF	Citations
145	Blood circulating tumor DNA for nonâ€invasive genotyping of colon cancer patients. Molecular Oncology, 2016, 10, 475-480.	4.6	52
146	Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene, 1997, 14, 705-711.	5.9	51
147	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E353-9.	7.1	51
148	Mutational profiling of kinases in glioblastoma. BMC Cancer, 2014, 14, 718.	2.6	50
149	PIK3CA-activating mutations and chemotherapy sensitivity in stage IIâ€“III breast cancer. Breast Cancer Research, 2008, 10, R27.	5.0	49
150	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repairâ€“Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discovery, 2021, 11, 1923-1937.	9.4	48
151	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	9.4	48
152	The status of tumor mutational burden and immunotherapy. Nature Cancer, 2022, 3, 652-656.	13.2	48
153	Mutational analysis of gene families in human cancer. Current Opinion in Genetics and Development, 2005, 15, 5-12.	3.3	47
154	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research, 2011, 17, 6531-6541.	7.0	47
155	Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal Cancer. Cancer Research, 2005, 65, 11227-11227.	0.9	45
156	p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells. Cancer Biology and Therapy, 2004, 3, 221-225.	3.4	44
157	Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes. PLoS ONE, 2012, 7, e36402.	2.5	43
158	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB Journal, 2015, 29, 464-476.	0.5	43
159	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	7.0	42
160	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Medicine, 2019, 11, 42.	8.2	42
161	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. Cancers, 2020, 12, 685.	3.7	42
162	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Human Mutation, 2009, 30, E451-E459.	2.5	41

#	Article	IF	Citations
163	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research, 2017, 23, 4312-4322.	7.0	41
164	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	6.4	41
165	Molecular profiling of the Ã¢Â€Âœplexinome Ã¢Â€Â•in melanoma and pancreatic cancer. Human Mutation, 2009, 30, 1167-1174.	2.5	40
166	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 80-83.	2.3	40
167	Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11412-11417.	7.1	38
168	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications, 2017, 8, 15617.	12.8	38
169	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S5.	7.7	37
170	Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. Oncotarget, 2016, 7, 58743-58758.	1.8	37
171	CD4 T Cellâ€“Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repairâ€“Deficient Tumors. Cancer Discovery, 2021, 11, 1844-1859.	9.4	37
172	Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nature Immunology, 2021, 22, 735-745.	14.5	36
173	Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-RasG13D. Biochemical and Biophysical Research Communications, 2009, 386, 593-597.	2.1	35
174	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1062-1067.	1.2	35
175	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Seminars in Cancer Biology, 2022, 84, 199-213.	9.6	35
176	Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells. Cancer Research, 2007, 67, 7088-7094.	0.9	34
177	Preclinical models for precision oncology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 239-246.	7.4	34
178	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
179	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. Pathobiology, 2018, 85, 146-154.	3.8	33
180	Towards a cancer mission in Horizon Europe: recommendations. Molecular Oncology, 2020, 14, 1589-1615.	4.6	33

#	Article	IF	Citations
181	Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. Biochemical Journal, 1998, 336, 235-239.	3.7	32
182	Knock-in of Oncogenic Kras Does Not Transform Mouse Somatic Cells But Triggers a Transcriptional Response that Classifies Human Cancers. Cancer Research, 2007, 67, 8468-8476.	0.9	32
183	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of Oncology, 2017, 28, 1302-1308.	1.2	32
184	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	3.7	32
185	Somatic alterations as the basis for resistance to targeted therapies. Journal of Pathology, 2014, 232, 244-254.	4.5	31
186	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. British Journal of Cancer, 2017, 117, 347-352.	6.4	31
187	Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica, 2010, 102, 119-26.	3.4	31
188	â€œInvasive-growthâ€•signaling by the Met/HGF receptor. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, M41-M51.	7.4	30
189	Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene, 2018, 37, 4599-4610.	5.9	30
190	KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. PLoS ONE, 2011, 6, e29146.	2.5	30
191	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	4.5	29
192	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Clinical Colorectal Cancer, 2019, 18, 91-101.e3.	2.3	29
193	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treatment Reviews, 2020, 91, 102112.	7.7	29
194	The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. Cell Reports, 2021, 35, 109252.	6.4	29
195	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Annals of Oncology, 2005, 16, 1848-1849.	1.2	28
196	Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology, 2010, 5, 19-28.	3.6	27
197	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents inÂmetastatic colorectal cancer patients. European Journal of Cancer, 2017, 71, 43-50.	2.8	27
198	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open, 2019, 4, e000572.	4.5	27

#	Article	IF	Citations
199	METPRC mutations in the ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. , 1999, 181, 507-514.		24
200	PRL-3: A phosphatase for metastasis?. Cancer Biology and Therapy, 2004, 3, 952-953.	3.4	24
201	Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. Clinical Cancer Research, 2014, 20, 6346-6356.	7.0	24
202	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treatment Reviews, 2016, 51, 54-62.	7.7	24
203	Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members. Cancer Letters, 2017, 389, 59-69.	7.2	24
204	Identification of cancer genes by mutational profiling of tumor genomes. FEBS Letters, 2005, 579, 1884-1890.	2.8	23
205	A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. Nature Genetics, 2022, 54, 976-984.	21.4	23
206	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology, 2019, 9, 622.	2.8	22
207	Climbing RAS, the Everest of Oncogenes. Cancer Discovery, 2014, 4, 19-21.	9.4	21
208	Liquid biopsies to evaluate early therapeutic response in colorectal cancer. Annals of Oncology, 2015, 26, 1525-1527.	1.2	19
209	Two main mutational processes operate in the absence of DNA mismatch repair. DNA Repair, 2020, 89, 102827.	2.8	19
210	Absence of AKT1 Mutations in Glioblastoma. PLoS ONE, 2009, 4, e5638.	2.5	19
211	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. Cellular and Molecular Life Sciences, 2013, 70, 4131-4140.	5.4	18
212	BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors. Molecular Cancer Therapeutics, 2013, 12, 2950-2961.	4.1	18
213	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature Communications, 2018, 9, 2287.	12.8	18
214	HER2 amplification as a â€˜molecular baitâ€™ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. Journal of Clinical Oncology, 2016, 34, TPS774-TPS774.	1.6	18
215	Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leukemia and Lymphoma, 2011, 52, 1742-1750.	1.3	17
216	Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas. PLoS ONE, 2010, 5, e12653.	2.5	16

#	Article	IF	Citations
217	Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis. Cancer Research, 2013, 73, 1912-1921.	0.9	15
218	Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a029587.	6.2	15
219	Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, djw209.	6.3	15
220	Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313.	4.4	15
221	Targeted Knock-in of the Polymorphism rs61764370 Does Not AffectKRASExpression but Reduces let-7 Levels. Human Mutation, 2014, 35, 208-214.	2.5	14
222	Minimal Residual Disease in Breast Cancer: In Blood Veritas. Clinical Cancer Research, 2014, 20, 2505-2507.	7.0	14
223	Does early metastatic seeding occur in colorectal cancer?. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 651-653.	17.8	14
224	Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. Neuropathology and Applied Neurobiology, 2019, 45, 655-670.	3.2	14
225	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS4124-TPS4124.	1.6	14
226	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. Cancers, 2022, 14, 241.	3.7	14
227	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget, 2015, 6, 10994-11008.	1.8	13
228	RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death and Disease, 2020, 11, 930.	6.3	12
229	EGFR Amplification in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1561-1569.	6.3	12
230	Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. Cancer Discovery, 2021, 11, 1886-1895.	9.4	12
231	Genomic landscapes of cancers: prospects for targeted therapies. Pharmacogenomics, 2007, 8, 1629-1633.	1.3	10
232	Isogenic mutant human cells: A new tool for personalized cancer medicine. Cell Cycle, 2010, 9, 20-21.	2.6	10
233	Personalized test tracks cancer relapse. Nature, 2017, 545, 417-418.	27.8	10
234	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10

#	Article	IF	Citations
235	Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridineâ€“resistant cancer cells. Molecular Cancer Therapeutics, 2005, 4, 1026-1030.	4.1	9
236	Kinase mutations in cancer: chinks in the enemyÊ¼s armour?. Current Opinion in Oncology, 2006, 18, 69-76.	2.4	9
237	Activation of Î²-Catenin by Oncogenic PIK3CA and EGFR Promotes Resistance to Glucose Deprivation by Inducing a Strong Antioxidant Response. PLoS ONE, 2012, 7, e37526.	2.5	9
238	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. Cancers, 2022, 14, 1197.	3.7	9
239	Inactivation of DNA repairâ€”prospects for boosting cancer immune surveillance. Genome Medicine, 2018, 10, 91.	8.2	8
240	Scatter Factor Receptors are Key Players in a Unique Multistep Program Leading to Invasive Growth. Novartis Foundation Symposium, 1997, 212, 133-154.	1.1	8
241	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. European Radiology, 2020, 30, 4496-4503.	4.5	7
242	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).. Journal of Clinical Oncology, 2013, 31, TPS3648-TPS3648.	1.6	7
243	Modeling Tumor Progression by the Sequential Introduction of Genetic Alterations into the Genome of Human Normal Cells. Human Mutation, 2013, 34, 330-337.	2.5	6
244	Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. Annals of Oncology, 2019, 30, 157-159.	1.2	6
245	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. Cancer Immunology Research, 2021, 9, 825-837.	3.4	6
246	Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. Cancers, 2021, 13, 3805.	3.7	6
247	Broccoli, PTEN deletion and prostate cancer: where is the link ?. Molecular Cancer, 2010, 9, 308.	19.2	5
248	Tracking colorectal cancer evolution in time and space. Annals of Oncology, 2017, 28, 1163-1165.	1.2	5
249	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precision Oncology, 2021, 5, 1192-1199.	3.0	5
250	Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines. Cancers, 2022, 14, 1230.	3.7	5
251	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. ESMO Open, 2016, 1, e000079.	4.5	3
252	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	3.8	3

#	Article	IF	Citations
253	Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patientsâ€™ avatars.. Journal of Clinical Oncology, 2014, 32, 2626-2626.	1.6	3
254	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2015, 33, TPS3632-TPS3632.	1.6	3
255	Understanding how kinase-targeted therapies work. Cell Cycle, 2008, 7, 1560-1563.	2.6	2
256	Mouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing?. Clinical Cancer Research, 2013, 19, 2794-2796.	7.0	2
257	Reply to E. Hawkes et al. Journal of Clinical Oncology, 2010, 28, e532-e533.	1.6	1
258	Tracking the genomic evolution of breast cancer metastasis. Breast Cancer Research, 2010, 12, 302.	5.0	0
259	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0
260	Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. Current Opinion in Molecular Therapeutics, 2010, 12, 703-11.	2.8	0
261	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomasâ€”A Preclinical and Translational Study. Cancers, 2021, 13, 6295.	3.7	0